ClinicalTrials.Veeva

Menu
V

Virginia Dermatology & Skin Cancer Center | Norfolk Office

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Amlitelimab
ENV-294
Ixekizumab
Guselkumab
BFB759

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 9 total trials

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis (COMPASS 2-AD)

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB75...

Enrolling
Atopic Dermatitis (AD)
Biological: BFB759
Drug: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Topical corticosteroids

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Active, not recruiting
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Invitation-only
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Topical corticosteroids

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.The mai...

Enrolling
Atopic Dermatitis (AD)
Drug: ENV-294
Drug: Placebo

Trial sponsors

Sanofi logo
E
AbbVie logo
Lilly logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems